

number, OMB number, and HCFA document identifier, to Paperwork@hcfa.gov, or call the Reports Clearance Office on (410) 786-1326. Written comments and recommendations for the proposed information collections must be mailed within 30 days of this notice directly to the OMB desk officer: OMB Human Resources and Housing Branch, Attention: Allison Eydt, New Executive Office Building, Room 10235, Washington, D.C. 20503.

Dated: February 18, 1998.

John P. Burke III,

HCFA Reports Clearance Officer, HCFA Office of Information Services, Information Technology Investment Management Group, Division of HCFA Enterprise Standards.

[FR Doc. 98-4864 Filed 2-25-98; 8:45 am]

BILLING CODE 4120-03-P

DEPARTMENT OF HEALTH AND HUMAN SERVICES

National Institutes of Health

National Institute of Allergy and Infectious Diseases; Opportunity for a Cooperative Research and Development Agreement (CRADA) To Develop Live Attenuated Dengue Viruses for Use as Vaccines in Humans

AGENCY: National Institutes of Health, Public Health Service, DHHS.

ACTION: Notice.

SUMMARY: The National Institute of Allergy and Infectious Diseases (NIAID) of the National Institutes of Health (NIH) is seeking capability statements from parties interested in entering into a Cooperative Research and Development Agreement (CRADA) on a project to develop live attenuated dengue viruses for use as vaccines to prevent dengue hemorrhagic fever and dengue shock syndrome in humans. This project is part of ongoing vaccine development activities in the Laboratory of Infectious Diseases (LID), Division of Intramural Research, NIAID.

DATES: Only written CRADA capability statements which are received by the NIAID on or before March 30, 1998 will be considered.

ADDRESSES: Capability statements should be submitted to Dr. Michael R. Mowatt, Office of Technology Development, National Institute of Allergy and Infectious Diseases, National Institutes of Health, 31 Center Drive MSC 2137, Building 31, Room 3B62, Bethesda, MD 20892-2137; Tel: 301/496-2644, Fax: 301/402-7123; Electronic mail: mmowatt@nih.gov.

SUPPLEMENTARY INFORMATION: The CRADA will employ attenuated dengue virus strains (types 1 through 4) developed in LID using recombinant DNA methodologies to (1) Identify and characterize the mutations responsible for attenuation, (2) engineer viral strains suitably attenuated for use as human vaccines, and (3) evaluate the attenuated viruses as live vaccines in animals and humans. The Public Health Service (PHS) has filed patent applications both in the U.S. and internationally related to these technologies.

The LID has extensive experience in evaluating the safety, antigenicity, immunogenicity and efficacy of various human viral pathogens and vaccines thereof both in experimental animals and human volunteers. The Collaborator in this endeavor would be required to provide and maintain at least four scientists off-site to support the CRADA Research Plan. These scientists would coordinate the production and release testing of the candidate vaccines, generate monoclonal antibodies needed for manufacture of clinical lots and for their clinical evaluation, and use molecular virologic techniques to generate attenuating mutations suitable for use in live vaccine candidates. In addition, it is expected that the Collaborator would provide funds to supplement LID's research budget for the project and would make a major funding commitment to support the safety, immunogenicity and efficacy studies for candidate vaccines developed and licensed under the CRADA.

The capability statement should include detailed descriptions of: (1) The technical expertise of the Collaborator's Principal Investigator and laboratory group in molecular virology, (2) Ability of Collaborator to manufacture at least four experimental vaccine lots per year, and (3) Ability to provide adequate and sustained funding to support the requisite vaccine safety and efficacy studies.

Dated: February 19, 1998.

Mark L. Rohrbaugh,

Director, Office of Technology Development, NIAID.

[FR Doc. 98-4880 Filed 2-25-98; 8:45 am]

BILLING CODE 4140-01-M

DEPARTMENT OF HEALTH AND HUMAN SERVICES

National Institutes of Health

National Cancer Institute; Notice of Closed Meeting

Pursuant to Section 10(d) of the Federal Advisory Committee Act, as amended (5 U.S.C. Appendix 2), notice is hereby given of the following National Cancer Institute Special Emphasis Panel (SEP) meeting:

Name of SEP: Polyvalent Vaccine Phase III Trial—Stage VI—Melanoma. Telephone Conference Call.

Date: March 17, 1998.

Time: 1 p.m. to Adjournment.

Place: National Cancer Institute, Executive Plaza North, Room 611C, 6130 Executive Boulevard, Bethesda, MD 20892-7403.

Contact Person: John L. Meyer, Ph.D., Scientific Review Administrator, National Cancer Institute, NIH, Executive Plaza North, Room 611C, 6130 Executive Boulevard, MSC 7403, Bethesda, MD 20892-7403, Telephone: 301/496-7721.

Purpose/Agenda: To review, discuss and evaluate grant applications.

The meeting will be closed in accordance with the provisions set forth in secs. 552b(c)(4) and 552b(c)(6), Title 5, U.S.C. Applications and the discussions could reveal confidential trade secrets or commercial property such as patentable material and personal information concerning individuals associated with the applications, the disclosure of which would constitute a clearly unwarranted invasion of personal privacy.

(Catalog of Federal Domestic Assistance Program Numbers: 93.393, Cancer Cause and Prevention Research; 93.394, Cancer Detection and Diagnosis Research; 93.395, Cancer Treatment Research; 93.396, Cancer Biology Research; 93.397, Cancer Centers Support; 93.398, Cancer Research Manpower; 93.399, Cancer Control)

Dated: February 19, 1998.

LaVeen Ponds,

Acting Committee Management Officer, National Institutes of Health.

[FR Doc. 98-4869 Filed 2-25-98; 8:45 am]

BILLING CODE 4140-01-M

DEPARTMENT OF HEALTH AND HUMAN SERVICES

National Institutes of Health

National Cancer Institute; Notice of Meetings

Pursuant to section 10(d) of the Federal Advisory Committee Act (FACA), as amended (5 U.S.C. Appendix 2) notice is hereby given of the advisory committee meetings listed below of the National Cancer Institute (NCI).

The meetings will be open to the public as indicated below, with attendance by the public limited to space available. Individuals who plan to attend and need special assistance, such as sign language interpretation or other reasonable accommodations, should contact Ms. Linda Quick-Cameron, Committee Management Officer, at (301) 496-5708, in advance of the meetings.

A portion of the meetings will be closed to the public in accordance with the provisions set forth in sections 552b(c)(4), 552b(c)(6), and 552b(c)(9)(B), Title 5 U.S.C., and section 10(d) of the FACA, for the review, discussion and evaluation of individual programs and for discussion of issues pertaining to programmatic areas and/or NCI personnel. These discussions could reveal confidential trade secrets or commercial property such as patentable material, and personal information concerning the individuals associated with the programs, including consideration of personnel qualifications and performances, the competence of individual investigators and similar matters, the disclosure of which would constitute a clearly unwarranted invasion of personal privacy and premature disclosure of recommendations which would likely significantly frustrate the subsequent implementation of recommendations.

The Committee Management Office, National Cancer Institute, National Institutes of Health, Executive Plaza North, Room 609, 6130 Executive Boulevard, MSC 7410, Rockville, Maryland 20892-7410, (301) 496-5708, will provide summaries of the meetings and rosters of the committee members, upon request.

Name of Committee: Advisory Committee to the Director, National Cancer Institute.

Contact Person: Susan J. Waldrop, Executive Secretary, National Cancer Institute, NIH, Federal Building, Room 312, Bethesda, MD 20892, (301) 496-1458.

Date of Meeting: March 1, 1998.

Place of Meeting: Hyatt Regency—Bethesda, One Bethesda Metro Center, Congressional Room, Bethesda, MD 20814.

Open: 7 p.m. to Adjournment.

Agenda: To update the Committee on the activities of the NCI Working Groups and on the groups reporting to the Advisory Committee to the Director, NCI.

Committee Name: Joint Meeting—National Cancer Institute Board of Scientific Advisors and Board of Scientific Counselors, National Cancer Institute.

Date: March 2, 1998.

Place: Building 31C, 6th Floor, Conference Room 10, National Institutes of Health, 9000 Rockville Pike, Bethesda, MD 20892.

Open: 8 a.m. to 9:20 a.m.

Agenda: Report of the Director, NCI.

Contact Person: Paulette S. Gray, Ph.D., Executive Secretary, National Cancer

Institute, NIH, Executive Plaza North, Room 600, 6130 Executive Blvd., MSC 7405, Bethesda, MD 20892-7405, (301) 496-4218.

Committee Name: National Cancer Institute Board of Scientific Advisors.

Date: March 2-3, 1998.

Place: Building 31C, 6th Floor, Conference Room 10, National Institutes of Health, 9000 Rockville Pike, Bethesda, MD 20892.

Open: March 2-9:30 a.m. to Recess; March 3-8 a.m. to Adjournment.

Agenda: RFA Concept Reviews, Report of the Deputy Director for Extramural Science, Status Reports of Implementing Program, Review Group(s) Recommendations, Budget Presentation and Status Reports from the Extramural Divisions.

Contact Person: Paulette S. Gray, Ph.D., Executive Secretary, National Cancer Institute, NIH, Executive Plaza North, Room 600, 6130 Executive Blvd., MSC 7405, Bethesda, MD 20892-7405, (301) 496-4218.

Committee Name: Joint Meeting—Board of Scientific Counselors, National Cancer Institute, Clinical Sciences and Epidemiology—Subcommittee A, Basic Sciences—Subcommittee B.

Date: March 2, 1998.

Place: Building 31C, 6th Floor, Conference Room 10, National Institutes of Health, 9000 Rockville Pike, Bethesda, MD 20892.

Closed: 9:20 a.m.—10:15 a.m.

Agenda: Discussion of Intramural Review Issues.

Contact Person: Florence Farber, Ph.D., Executive Secretary, National Cancer Institute, NIH, Executive Plaza North, Room 643G, 6130 Executive Blvd., MSC 7410, Bethesda, MD 20892-7410, (301) 496-2378.

Committee Name: Board of Scientific Counselors, National Cancer Institute, Clinical Sciences and Epidemiology—Subcommittee A.

Date: March 2, 1998.

Place: Building 31C, 6th Floor, Conference Room 6, National Institutes of Health, 9000 Rockville Pike, Bethesda, MD 20892.

Closed: 10:30 a.m. to Adjournment.

Agenda: To discuss administrative confidential matters pertaining to the Division of Clinical Sciences and the Division of Cancer Epidemiology and Genetics.

Contact Person: Judy Mietz, Ph.D., Executive Secretary, National Cancer Institute, NIH, Executive Plaza North, Room 600, 6130 Executive Blvd., MSC 7410, Bethesda, MD 20892-7410, (301) 496-2378.

Committee Name: Board of Scientific Counselors, National Cancer Institute Basic Sciences—Subcommittee B.

Date: March 2, 1998.

Place: Building 31C, 6th Floor, Conference Room 8, National Institutes of Health, 9000 Rockville Pike, Bethesda, MD 20892.

Closed: 10:30 a.m. to Adjournment.

Agenda: To discuss administrative confidential matters and site visit reports pertaining to the laboratories in the Division of Basic Sciences.

Contact Person: Florence Farber, Ph.D., Executive Secretary, National Cancer Institute, NIH, Executive Plaza North, Room 643G, 6130 Executive Blvd., MSC 7410, Bethesda, MD 20892-7410, (301) 496-2378.

This notice is being published less than 15 days prior to the meeting due to the urgent need to meet timing limitations imposed by the review and funding cycle.

(Catalog of Federal Domestic Assistance Program Numbers: 93.393, Cancer Cause and Prevention Research; 93.394, Cancer Detection and Diagnosis Research; 93.395, Cancer Treatment Research; 93.396, Cancer Biology Research; 93.397, Cancer Centers Support; 93.398, Cancer Research Manpower; 93.399, Cancer Control)

Dated: February 17, 1998.

LaVeen Ponds,

*Acting Committee Management Officer,
National Institutes of Health.*

[FR Doc. 98-4881 Filed 2-25-98; 8:45 am]

BILLING CODE 4140-01-M

DEPARTMENT OF HEALTH AND HUMAN SERVICES

National Institutes of Health

National Center for Research Resources; Notice of Closed Meeting

Pursuant to Section 10(d) of the Federal Advisory Committee Act, as amended (5 U.S.C. Appendix 2), notice is hereby given of the following National Center for Research Resources Special Emphasis Panel (SEP) meeting:

Name of SEP: Comparative Medicine.

Date: March 9-10, 1998.

Time: March 9, 7-9 p.m.; March 10, 1-3 p.m.

Place: Clarion Hotel and Conference Center, 4345 North Lincoln Boulevard, Oklahoma City, OK 73105, (405) 528-2741.

Contact Person: Dr. Bela J. Gulyas, Scientific Review Administrator, 6705 Rockledge Drive, MSC 7965, Room 6018, Bethesda, MD 20892-7965, (301) 435-0811.

Purpose/Agenda: To evaluate and review grant applications.

This notice is being published less than 15 days prior to the above meeting due to the urgent need to meet timing limitations imposed by the review and funding cycle.

This meeting will be closed in accordance with the provisions set forth in secs. 552b(c)(4) and 552b(c)(6), Title 5, U.S.C. Applications and/or proposals and the discussions could reveal confidential trade secrets or commercial property such as patentable material and personal information concerning individuals associated with the applications and/or proposals, the disclosure of which would constitute a clearly unwarranted invasion of personal privacy. (Catalog of Federal Domestic Assistance Program No. 93.306, Laboratory Animal Science and Primate Research, National Institutes of Health, HHS)

Dated: February 18, 1998.

LaVeen M. Ponds,

*Acting Committee Management Officer,
National Institutes of Health.*

[FR Doc. 98-4876 Filed 2-25-98; 8:45 am]

BILLING CODE 4140-01-M